Coya Therapeutics Future Growth
Future criteria checks 2/6
Coya Therapeutics is forecast to grow earnings and revenue by 7.9% and 27.2% per annum respectively while EPS is expected to grow by 16.3% per annum.
Key information
7.9%
Earnings growth rate
16.3%
EPS growth rate
| Biotechs earnings growth | 27.3% |
| Revenue growth rate | 27.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 10 Mar 2025 |
Recent future growth updates
Recent updates
Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth
Oct 29
Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts
Oct 13Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans
Mar 26Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
Feb 13Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position
Jan 13We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully
Sep 06Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation
May 17Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 15 | -15 | -30 | -15 | 1 |
| 12/31/2026 | 5 | -26 | -40 | -30 | 2 |
| 12/31/2025 | 6 | -22 | -29 | -25 | 5 |
| 12/31/2024 | 4 | -17 | -22 | -11 | 5 |
| 9/30/2024 | 10 | -11 | -10 | -10 | N/A |
| 6/30/2024 | 10 | -10 | -7 | -7 | N/A |
| 3/31/2024 | 6 | -10 | -6 | -5 | N/A |
| 12/31/2023 | 6 | -8 | -12 | -11 | N/A |
| 9/30/2023 | N/A | -12 | -12 | -11 | N/A |
| 6/30/2023 | N/A | -13 | -11 | -11 | N/A |
| 3/31/2023 | N/A | -13 | -10 | -9 | N/A |
| 12/31/2022 | N/A | -12 | -8 | -7 | N/A |
| 9/30/2022 | N/A | -11 | -6 | -6 | N/A |
| 6/30/2022 | N/A | -8 | -6 | -6 | N/A |
| 3/31/2022 | N/A | -6 | -5 | -5 | N/A |
| 12/31/2021 | N/A | -5 | -4 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COYA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: COYA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: COYA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: COYA's revenue (27.2% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: COYA's revenue (27.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if COYA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/14 00:07 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Coya Therapeutics, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Keay Nakae | Chardan Capital Markets, LLC |
| Jason Kolbert | D. Boral Capital LLC. |